BETA

Beta Pharma, also known as Betta Pharmaceuticals, is a leading innovative pharmaceutical company primarily focused on the discovery, development, and commercialization of targeted oncology therapies. The company achieved a major milestone in the Chinese pharmaceutical industry with the development and launch of Icotinib (Conmana), the first self-developed innovative small-molecule targeted drug in China for non-small-cell lung cancer. Beta Pharma maintains a robust pipeline of precision medicines, including next-generation EGFR inhibitors, ALK inhibitors, and CDK4/6 inhibitors. With fully integrated capabilities spanning from early-stage research to large-scale manufacturing and commercial sales, the company has established itself as a dominant player in the lung cancer market. Beta Pharma continues to expand its global footprint through strategic partnerships and a diverse portfolio of small molecules and biologics targeting unmet medical needs in oncology.